TONMYA was approved by the FDA on August 15, 2025.

TONMYA (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic taken once daily at bedtime for adults with fibromyalgia. The treatment was approved by the FDA on August 15, 2025, marking ...

TONMYA is now available by prescription and available for pharmacy ordering nationwideTONMYA is the first FDA-approved treatment for fibromyalgia ...

Tonix prepares for the November 2025 launch of Tonmya with 3Q25 revenue growth, strong cash, higher SG&A, and a robust ...

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), ...

Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in NovemberTonmya is the first new FDA-approved ...

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today ...

Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and ...

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...

Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally ...